


Bismar TA, Yoshimoto M, Duan QL, Liu SH, Sircar K, Squire JA. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology. 2012 Mar; 60 (4) 645-652


Daze KD, Pinter T, Beshara CS, Ibraheem A, Minaker SA, Ma MCF, Courtemanche RJM, Campbell RE, Hof F. Supramolecular hosts that recognize methyllysines and disrupt the interaction between a modified histone tail and its epigenetic reader protein. Chemical Science. 2012 3 (9) 2695-2699


Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer Letters. 2012 Feb; 315 (1) 38-47


Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene. 2012 Sep; 31 (37) 4164-4170


Klotz L. Active surveillance: the Canadian experience. Current Opinion in Urology. 2012 May; 22 (3) 222-230


Lowes Lori E, Hedley Benjamin D, Keeney Mike, Allan Alison L. User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch® system. Cytometry Part A. 2012 Nov; 81 983-995


Metser U, Goldstein MA, Chawla TP, Fleshner NE, Jacks LM, O'Malley ME. Detection of Urothelial Tumors: Comparison of Urothelial Phase with Excretory Phase CT Urography-A Prospective Study. Radiology. 2012 July; 264 (1) 110-118


Petraki C, Dubinski W, Scorilas A, Saleh C, Pasic MD, Komborozos V, Khalil B, Gabril MY, Streutker C,


Twiddy Alexis L, Cox Michael E, Wasan Kishor M. Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate. 2012 Jun; 72 955-965


